» Articles » PMID: 33236288

Nerve Growth Factor is a Potential Treated Target in Tg(SOD1*G93A)1Gur Mice

Overview
Publisher Springer
Date 2020 Nov 25
PMID 33236288
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Nerve growth factor (NGF) is a protective factor of neural cells; the possible relationship between the NGF and the pathogenesis of amyotrophic lateral sclerosis (ALS) hasn't been completely known. In this study, we observed and analyzed the expression and distribution of NGF, as well as the possible relationship between the NGF expression and distribution and the neural cell death in both SOD1 wild-type (WT) and Tg(SOD1*G93A)1Gur (TG) mice applying the fluorescence immunohistochemistry method. The results showed that the expression and distribution of NGF in the anterior horn (AH), the lateral horn (LH), and the surrounding central canal (CC) significantly increased at the supper early stage of ALS (Pre-onset stage) and the early stage (Onset stage), but the NGF expression and distribution in the AH, the LH, and the surrounding CC significantly reduced at the progression stage. The astrocyte, neuron, and oligodendrocyte produced the NGF and the neural precursor cells (NPCs) produced the NGF. The neural cell death gradually increased accompanying with the reduction of NGF expression and distribution. Our data suggested that the NGF was a protective factor of neural cells, because the neural cells in the AH, the LH, and the surrounding CC produced more NGF at the supper early and early stage of ALS; moreover, the NPCs produced the NGF. It implied that the NGF exerted the protective effect of neural cells, prevented from the neural cell death and aroused the potential of self-repair in the development of ALS.

Citing Articles

The History of Nerve Growth Factor: From Molecule to Drug.

Gavioli E, Mantelli F, Cesta M, Sacchetti M, Allegretti M Biomolecules. 2024; 14(6).

PMID: 38927039 PMC: 11201509. DOI: 10.3390/biom14060635.

References
1.
Kaplan D, Stephens R . Neurotrophin signal transduction by the Trk receptor. J Neurobiol. 1994; 25(11):1404-17. DOI: 10.1002/neu.480251108. View

2.
Dash R, Jayachandra Babu R, Srinivas N . Two Decades-Long Journey from Riluzole to Edaravone: Revisiting the Clinical Pharmacokinetics of the Only Two Amyotrophic Lateral Sclerosis Therapeutics. Clin Pharmacokinet. 2018; 57(11):1385-1398. DOI: 10.1007/s40262-018-0655-4. View

3.
Oskarsson B, Gendron T, Staff N . Amyotrophic Lateral Sclerosis: An Update for 2018. Mayo Clin Proc. 2018; 93(11):1617-1628. DOI: 10.1016/j.mayocp.2018.04.007. View

4.
McManus M, Franklin J . Dissociation of JNK Activation from Elevated Levels of Reactive Oxygen Species, Cytochrome c Release, and Cell Death in NGF-Deprived Sympathetic Neurons. Mol Neurobiol. 2016; 55(1):382-389. DOI: 10.1007/s12035-016-0332-2. View

5.
Aquilonius S, Askmark H, Ebendal T, Gillberg P . No re-expression of high-affinity nerve growth factor binding sites in spinal motor neurons in amyotrophic lateral sclerosis. Eur Neurol. 1992; 32(4):216-8. DOI: 10.1159/000116825. View